A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas

Journal of Neurochemistry

Volumn 109, Issue 4, 2009, Pages 1079-1086

  Akazawa, Toshimasa ^a   Kwatra, Shawn G ^a   Goldsmith, Laura E ^a   Richardson, Mark D ^a   Cox, Elizabeth A ^a   Sampson, John H ^b   Kwatra, Madan M ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Akt; Apoptosis; Glioblastoma; Neurokinin 1 receptor

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUROKININ 1 RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SUBSTANCE P;

APOPTOSIS; ARTICLE; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 65649138814     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06032.x     Document Type: Article

References (46)

1. Amadoro G., Pieri M., Ciotti M. T., Carunchio I., Canu N., Calissano P., Zona C. Severini C. (2007) Substance P provides neuroprotection in cerebellar granule cells through Akt and MAPK/Erk activation: evidence for the involvement of the delayed rectifier potassium current. Neuropharmacology 52, 1366 1377. (Pubitemid 46601528)
2. Belmokhtar C. A., Hillion J. Segal-Bendirdjian E. (2001) Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene 20, 3354 3362. (Pubitemid 32588984)
3. Berger A. Paige C. J. (2005) Hemokinin-1 has Substance P-like function in U-251 MG astrocytoma cells: a pharmacological and functional study. J. Neuroimmunol. 164, 48 56. (Pubitemid 40826762)
4. Boatright K. M. Salvesen G. S. (2003) Mechanisms of caspase activation. Curr. Opin. Cell Biol. 15, 725 731. (Pubitemid 37492933)
5. Caberlotto L., Hurd Y. L., Murdock P., Wahlin J. P., Melotto S., Corsi M. Carletti R. (2003) Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur. J. Neurosci. 17, 1736 1746. (Pubitemid 36645323)
6. Cappuzzo F. (2005) Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? J. Natl Cancer Inst. 97, 868 869. (Pubitemid 41417931)
7. Castagliuolo I., Valenick L., Liu J. Pothoulakis C. (2000) Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J. Biol. Chem. 275, 26545 26550.
8. Chakravarti A., Zhai G., Suzuki Y., Sarkesh S., Black P. M., Muzikansky A. Loeffler J. S. (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 22, 1926 1933. (Pubitemid 41095185)
9. Chang C. Y., Li M. C., Liao S. L., Huang Y. L., Shen C. C. Pan H. C. (2005) Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J. Clin. Neurosci. 12, 930 933.
10. Cheng J. Q., Altomare D. A., Klein M. A., Lee W. C., Kruh G. D., Lissy N. A. Testa J. R. (1997) Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 14, 2793 2801. (Pubitemid 27313411)
11. Choe G., Horvath S., Cloughesy T. F., Crosby K., Seligson D., Palotie A., Inge L., Smith B. L., Sawyers C. L. Mischel P. S. (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63, 2742 2746. (Pubitemid 36667143)
12. Davis F. G., Freels S., Grutsch J., Barlas S. Brem S. (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 88, 1 10. (Pubitemid 28018957)
13. Dudek H., Datta S. R., Franke T. F., Birnbaum M. J., Yao R., Cooper G. M., Segal R. A., Kaplan D. R. Greenberg M. E. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275, 661 665. (Pubitemid 27061332)
14. Fong T. M., Anderson S. A., Yu H., Huang R. R. Strader C. D. (1992) Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol. Pharmacol. 41, 24 30.
15. Giles G. G. Gonzales M. F. (2001) Epidemiology of brain tumors and factors in prognosis, in Brain Tumors, 2nd Edn (Kaye A. H. Laws Jr. E. R., eds), pp. 51 70. Churchill Livingstone, New York.
16. Green S. A., Alon A., Ianus J., McNaughton K. S., Tozzi C. A. Reiss T. F. (2006) Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J. Urol. 176, 2535 2540 Discussion 2540. (Pubitemid 44665982)
17. Haas-Kogan D. A., Prados M. D., Tihan T. et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97, 880 887. (Pubitemid 41417939)
18. Hennig I. M., Laissue J. A., Horisberger U. Reubi J. C. (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int. J. Cancer 61, 786 792.
19. Julien S., Puig I., Caretti E., Bonaventure J., Nelles L., van Roy F., Dargemont C., de Herreros A. G., Bellacosa A. Larue L. (2007) Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 26, 7445 7456. (Pubitemid 350158710)
20. Karamouzis M. V., Grandis J. R. Argiris A. (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298, 70 82. (Pubitemid 47026772)
21. Keller M., Montgomery S., Ball W. et al. (2006) Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59, 216 223. (Pubitemid 43208967)
22. Koon H. W., Zhao D., Zhan Y., Moyer M. P. Pothoulakis C. (2007) Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc. Natl Acad. Sci. USA 104, 2013 2018. (Pubitemid 46239895)
23. Kramer M. S., Winokur A., Kelsey J. et al. (2004) Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29, 385 392. (Pubitemid 38180456)
24. Li H., Leeman S. E., Slack B. E., Hauser G., Saltsman W. S., Krause J. E., Blusztajn J. K. Boyd N. D. (1997) A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization. Proc. Natl Acad. Sci. USA 94, 9475 9480. (Pubitemid 27357854)
25. Lieb K., Fiebich B. L., Berger M., Bauer J. Schulze-Osthoff K. (1997) The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J. Immunol. 159, 4952 4958. (Pubitemid 127471032)
26. Luo W., Sharif T. R. Sharif M. (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res. 56, 4983 4991. (Pubitemid 26374439)
27. Mendelsohn J. Baselga J. (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550 6565. (Pubitemid 32197693)
28. Munoz M. Rosso M. (2009) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest. New Drugs [Epub ahead of print] doi :.
29. Nagai S., Washiyama K., Kurimoto M., Takaku A., Endo S. Kumanishi T. (2002) Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J. Neurosurg. 96, 909 917. (Pubitemid 34415406)
30. Nicholson D. W., Ali A., Thornberry N. A. et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376, 37 43.
31. Ozes O. N., Mayo L. D., Gustin J. A., Pfeffer S. R., Pfeffer L. M. Donner D. B. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82 85. (Pubitemid 29418447)
32. Palma C. Maggi C. A. (2000) The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci. 67, 985 1001. (Pubitemid 30485803)
33. Palma C., Goso C. Manzini S. (1994) Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line. Neurosci. Lett. 171, 221 224. (Pubitemid 24142129)
34. Palma C., Bigioni M., Irrissuto C., Nardelli F., Maggi C. A. Manzini S. (2000) Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br. J. Cancer 82, 480 487. (Pubitemid 30045401)
35. Patel H. J., Ramkissoon S. H., Patel P. S. Rameshwar P. (2005) Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc. Natl Acad. Sci. USA 102, 17436 17441. (Pubitemid 41740884)
36. Ramkissoon S. H., Patel P. S., Taborga M. Rameshwar P. (2007) Nuclear factor-kappaB is central to the expression of truncated neurokinin-1 receptor in breast cancer: implication for breast cancer cell quiescence within bone marrow stroma. Cancer Res. 67, 1653 1659. (Pubitemid 46383391)
37. Raychaudhuri B., Han Y., Lu T. Vogelbaum M. A. (2007) Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J. Neurooncol. 85, 39 47. (Pubitemid 47422655)
38. Raymond E., Faivre S. Armand J. P. (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl 1, 15 23 Discussion 41-42.
39. Richardson M. D., Balius A. M., Yamaguchi K., Freilich E. R., Barak L. S. Kwatra M. M. (2003) Human substance P receptor lacking the C-terminal domain remains competent to desensitize and internalize. J. Neurochem. 84, 854 863. (Pubitemid 36176942)
40. Rolhion C., Penault-Llorca F., Kemeny J. L., Lemaire J. J., Jullien C., Labit-Bouvier C., Finat-Duclos F. Verrelle P. (2001) Interleukin-6 overexpression as a marker of malignancy in human gliomas. J. Neurosurg. 94, 97 101. (Pubitemid 32799478)
41. Salcman M. (2001) Glioblastoma multiforme and anaplastic astrocytoma, in Brain Tumors, 2nd Edn (Kaye A. H. Laws Jr. E. R., eds), pp. 493 523. Harcourt Publishers Limited, New York.
42. Shinojima N., Tada K., Shiraishi S. et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63, 6962 6970. (Pubitemid 37322983)
43. Tewari M., Quan L. T., O'Rourke K., Desnoyers S., Zeng Z., Beidler D. R., Poirier G. G., Salvesen G. S. Dixit V. M. (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, 801 809.
44. Waksal H. W. (1999) Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. 18, 427 436. (Pubitemid 30365321)
45. Yamaguchi K., Richardson M. D., Bigner D. D. Kwatra M. M. (2005) Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta. Cancer Chemother. Pharmacol. 56, 585 593. (Pubitemid 41425054)
46. Zhang Y., Lu L., Furlonger C., Wu G. E. Paige C. J. (2000) Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat. Immun. 1, 392 397.